Clin2
NCT06862453Possibly a fitRecruiting

Safety of a new malaria vaccine in healthy adults

Malaria Falciparum

Treatments studied

Part of Infections clinical trials.

This study tests a new malaria vaccine in healthy adults. You will receive the vaccine and then be exposed to the malaria parasite in a controlled setting to check if the vaccine protects you.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
58 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You are a healthy adult between 18 and 45 years old.
  • You have never received a malaria vaccine before.
  • You do not have any serious medical conditions like sickle cell disease, seizures, or heart problems.
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study.
  • You agree not to travel to a malaria-prone area for the duration of the trial.
  • You are willing to use effective birth control if you could become pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06958198Recruiting· Phase 1
Testing a new multi-stage malaria vaccine in adults and children

This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.

Siglé, Boulkiemdé Province
NCT06881732Not yet recruiting· Phase 1
Testing a new malaria vaccine by mosquito bite

This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.

Melbourne, Victoria
NCT07646353Not yet recruiting· Phase 1
Safety study of GSK4425689A in healthy adults

This is an early-stage safety study testing a new experimental drug (GSK4425689A) in healthy volunteers. Researchers want to find safe doses and understand how the body processes this medication.

NCT07545681Not yet recruiting· Phase 2
Testing a new malaria treatment for uncomplicated P. falciparum

This study tests a new experimental antimalarial drug (GSK3772701) to see if it can safely and effectively treat uncomplicated malaria caused by P. falciparum parasites. You would receive the study drug by mouth and be monitored closely with blood tests and heart rhythm checks.

NCT05790889Recruiting· Phase 1/Phase 2
Study of an experimental malaria vaccine in babies in Burkina Faso

This Phase 1/2 study tests a new vaccine meant to protect young children against malaria. If you qualify, your baby would get the study vaccine and be followed for about 12 months to check safety and early signs of protection.

Siglé, Boulkiemdé Province
NCT07011511Recruiting· Phase 1
Testing a new malaria drug in healthy volunteers

This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.

Nottingham

Hear when a new Malaria Falciparum trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.